Seattle Genetics has interim data for Adcetris in cutaneous T-cell lymphoma

Submitted by Ross Bonander Thu 01/26/2012

Share on Tumblr

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Seattle Genetics is announcing interim results from an investigator-sponsored phase II clinical trial of the company's lead oncology product Adcetris® (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL). The results are being announced at the T-Cell Lymphoma Forum between January 26-28, 2012 in San Francisco.

23 patients were enrolled in the phase II trial, and 17 of them had received at least two doses of the antibody drug conjugate and therefore could be evaluated. These patients were diagnosed with relapsed CD30-positive cutaneous lymphoproliferative disorders, including:

-- Lymphomatoid papulosis (LyP)
-- Primary cutaneous anaplastic large cell lymphoma (pcALCL)
-- Mycosis fungoides (MF)

Of the 17 patients, 11 of them or 65 % achieved an objective response, including seven complete remissions (CRs) and four partial remissions (PRs). Six patients had stable disease.

Source: MarketWatch

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Support Groups

SupportGroups.com

For individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Cancer Support Groups

Find a Treatment Facility Near You

Click on a state below to find Lymphoma treatment options that could be right for you.

Select a State Below

The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.